港股異動丨海普瑞大漲12%創近3年半新高 年內股價逼近翻倍 市值重回百億!
海普瑞(9989.HK)今日盤中一度大漲12.56%至7.26港元,股價創2022年2月15日以來近3年半新高,年內累漲約97%,市值重回100億港元上方。海普瑞公告,公司近期已完成其自主研發的創新候選藥物H1710注射液(“H1710”)的I期臨牀試驗首例受試者入組及首次給藥。H1710是一種低抗凝活性的肝素衍生物,是公司自主研發的高效高選擇性的乙醯肝素酶抑制劑。乙醯肝素酶在多種惡性腫瘤中高表達,並且與腫瘤的生長和轉移密切相關。H1710通過抑制乙醯肝素酶的活性和表達,展現出抗腫瘤作用。作爲靶向乙醯肝素酶的全新化合物,H1710具有更爲合理的鏈長和獨特的柔性結構,是一種高效、高選擇性的乙醯肝素酶抑制劑。光大證券發研報指,港股醫藥板塊估值收縮已持續數年,部分優質企業PE估值在反彈後仍具吸引力。考慮到部分創新藥公司BD交易持續催化、細分賽道及正處於轉型階段的公司或有積極變化,應當積極關注板塊高質量標的、增加板塊配置。細分子板塊內的部分優質企業的股價下行風險有限,具備長期投資價值,建議投資者關注板塊高質量、低估值公司的價值投資機會。(格隆匯)

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.